YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Innoviva (INVA) or Merck (MRK). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to fin…
Investing in stocks based on valuation metrics is a proven strategy for identifying companies with strong upside potential. Although the price-to-earnings (P/E) ratio is widely used to assess value, it becomes less meaningful when a compan…
Merck (MRK) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to earnings of $2.13 per share a year ago. These figures are adjusted for non-recurring items. This quarter…
AbbVie (ABBV) came out with quarterly earnings of $3.65 per share, beating the Zacks Consensus Estimate of $3.64 per share. This compares to earnings of $2.97 per share a year ago. These figures are adjusted for non-recurring items. This q…
[Stock market activity shows price changes and trading movements in real time] FabrikaCr As the market moves through second-quarter earnings season, investors are paying close attention to small-cap stocks that combine solid profitability…
Innoviva, Inc. (NASDAQ:INVA) is one ofthe best cheap small cap stocks to buy now. Nortiva Bio, Inc., which is a wholly owned subsidiary of Innoviva, Inc. (NASDAQ:INVA), announced on June 18 its launch as a clinical-stage biopharmaceutical…
AbbVie (ABBV) shares ended the last trading session 4.2% higher at $253.35. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.2% gain over the p…
Bayer Aktiengesellschaft (BAYRY) shares rallied 17% in the last trading session to close at $13.16. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the…
We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Innoviva, Inc. (NASDAQ:INVA) is one of the most promising stocks on our list. TheFly reported on June 18 that INVA announced the launch…
Innoviva Inc. (NASDAQ:INVA) is one of the most profitable undervalued stocks to invest in. On June 16, Innoviva Specialty Therapeutics entered an exclusive licensing and distribution agreement with Dr. Reddy's Laboratories to bring XACDURO…
[Growth bar graph] Dougal Waters As U.S. corporate profit margins remain near historic highs, investors are increasingly looking for companies that can translate strong operating performance into sustained earnings growth. Recent data from…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Healthcare stocks have remained in focus as investors look for companies that can deliver strong operational growth w…
BURLINGAME, Calif., June 01, 2026--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platfo…
Key Points Dauntless Investment Group bought 116,863 shares of Innoviva in an estimated trade of $2.52 million last quarter. The quarter-end position value rose by $2.74 million, reflecting both trading and price movements. The post-trade…
Innoviva, Inc. (NASDAQ:INVA) is one of the best small-cap value stocks to buy. On April 8, Cantor Fitzgerald reiterated an Overweight rating on Innoviva Inc. (NASDAQ:INVA) and a $32 price target. The research firm remains confident about t…
Pfizer (PFE) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.92 per share a year ago. These figures are adjusted for non-recurring items. This qu…
Merck (MRK) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.51. This compares to earnings of $2.22 per share a year ago. These figures are adjusted for non-recurring items. This quarter…
This drug stock has used recent declines as an opportunity to build a bullish base. Analysts see hearty price gains ahead. Continue Reading
Sarissa Capital Management established a new position in Biohaven Ltd.(NYSE:BHVN) during the fourth quarter, acquiring 513,184 shares worth $5.79 million at quarter’s end, according to a February 17, 2026, SEC filing. What happened Accordi…
Aurinia Pharmaceuticals announced a complete overhaul of its C-suite on Monday, sparking both the biotech stock and hopes of an acquisition. Continue Reading
Innoviva, Inc. (NASDAQ:INVA) is one of the best cheap biotech stocks to buy now. Cantor Fitzgerald lifted the price target on Innoviva, Inc. (NASDAQ:INVA) to $32 from $31 on February 26, maintaining an Overweight rating on the shares. The…
We came across a bullish thesis on Innoviva, Inc on Deep-Value Stocks’s Substack. In this article, we will summarize the bulls’ thesis on INVA. Innoviva, Inc's share was trading at $22.48 as of February 11th. INVA’s trailing and forward P/…
Innoviva logo Key Points Innoviva has shifted to a three-part model—royalties (Breo/ANORO yielded $250 million gross last year), a growing commercial platform (Innoviva Specialty Therapeutics with ~$120 million U.S. sales in 2025, targetin…
On Thursday, Celldex Therapeutics stock received an upgrade to its Relative Strength (RS) Rating, from 63 to 88. This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price ac…
Nurix Therapeutics stock now meets that criteria, with a jump from 77 to 82 Wednesday. IBD's unique RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the las…
CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating Continue Reading
Xenon Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating Continue Reading
AtaiBeckley names Michael Faerm as finance chief Proactive uses images sourced from Shutterstock AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as…
Bayer Aktiengesellschaft (BAYRY) shares ended the last trading session 6% higher at $14.4. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.9% g…
Eli Lilly (LLY) came out with quarterly earnings of $7.54 per share, beating the Zacks Consensus Estimate of $6.99 per share. This compares to earnings of $5.32 per share a year ago. These figures are adjusted for non-recurring items. This…
Innoviva, Inc. (NASDAQ:INVA) is one of the best small cap stocks to buy with huge upside potential. Innoviva, Inc. (NASDAQ:INVA) received a rating update from H.C. Wainwright on December 16, who lifted the price target to $46 from $45 whil…
[Stock market Graph] bluebay2014/iStock via Getty Images Charles Schwab’s chief investment strategist Liz Ann Sonders expects the market to continue broadening beyond top performers in 2026. In an interview by CNBC, Sonders noted that whil…
(RTTNews) - Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (INVA), announced that the U.S. Food and Drug Administration approved NUZOLVENCE (zoliflodacin) for oral suspension, a first-in-class, single-dose oral medication…
(RTTNews) - Every month, several health-awareness campaigns are conducted, and December, despite being a festive holiday season, is no different. Two major global and national health campaigns are recognized in December - World AIDS Day (D…
In trading on Friday, shares of Innoviva Inc (Symbol: INVA) crossed above their 200 day moving average of $18.61, changing hands as high as $18.66 per share. Innoviva Inc shares are currently trading up about 1.1% on the day. The chart bel…
(RTTNews) - Innoviva, Inc. (INVA) reported earnings for its third quarter that Increased, from last year The company's bottom line totaled $89.91 million, or $1.08 per share. This compares with $1.21 million, or $0.02 per share, last year.…